EUCTR2020-003545-11-DK进行中（未招募）1 期
A randomized phase III trial with lomustine versus lomustine and bevacizumab for patients with recurrent glioblastoma. - DNOG-LOBE-01
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 168
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histological verified glioblastoma
- •Recurrent GBM, previously treated according the STUPP regimen
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 84
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 84
排除标准
- •Previous therapy of recurrent GBM including temozolomide reinduction.
- •Previous use of biological drug targeting the VEGF-signaling pathway
研究者
相似试验
招募中
1 期
A Phase 1 Study of Lomustine and PCV in Japanese Patients with GliomaGliomaJPRN-jRCT2051230069ARAKAWA Yoshiki24
进行中（未招募）
1 期
A randomized, Phase III study of Fotemustine versus the Combination of Fotemustine and Ipilimumab in Patients with Metastatic Melanoma with brain metastasisEUCTR2012-004301-27-ITFONDAZIONE NIBIT160
进行中（未招募）
1 期
A randomized phase III trial of exemestane versus anastrozole in postmenopausal women with receptor positive primary breast cancer - MA.27Post-menopausal women, histologically or cytologically confirmed, receptor-positive,adequately excised, primary breast cancerEUCTR2005-001893-28-HUInternational Breast Cancer Study Group (IBCSG)7,576
进行中（未招募）
1 期
A randomized phase III trial of exemestane versus anastrozole in postmenopausal women with receptor positive primary breast cancer - MA.27EUCTR2005-001893-28-BEInternational Breast Cancer Study Group (IBCSG)5,800
已完成
3 期
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial).10038666Small cell lung cancerNL-OMON46847Pharma Mar18